Momat C, 0.1%, 15 g

Active ingredients:

mometasone furoate 0.1 g; 

salicylic acid 5 g;

Excipients: 

white petroleum jelly; 

beeswax white; 

propylene glycol monostearate;

hexylene glycol.

Momat-S is a drug with anti-inflammatory and keratolytic action for external use.
Mometasone furoate is a potent GCS. It has anti-inflammatory, antipruritic and vasoconstrictor effects. 

GCS induces the release of proteins (lipocortins) that inhibit phospholipase A2. Lipocortins control the biosynthesis of potent inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.

Arachidonic acid is released from membrane phospholipids by phospholipase A2. In vitro it was shown that mometasone furoate inhibits the synthesis of cytokines - interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α ), which are involved in the inflammatory process. 

Salicylic acid causes exfoliation of the stratum corneum of the skin and, at the same time, does not lead to qualitative or quantitative changes in the structure of the viable epidermis. This mechanism of action is explained by the dissolution of the intercellular binder.

Psoriasis, atopic dermatitis and other dermatoses, incl. in the scalp; allergic rhinitis, seasonal and chronic (treatment and prevention).

- Bacterial, viral (caused by herpes simplex virus, chickenpox, shingles) or fungal skin infections;
- rosacea;
- perioral dermatitis;
- post-vaccination reactions;
- tuberculosis of the skin;
- syphilis;
- age up to 12 years;
- pregnancy;
- lactation period;
- hypersensitivity to mometasone furoate, salicylic acid or to any other component of Momat-S.

The drug should be prescribed with caution in inflammatory diseases (including peripheral vessels), irritation or infection of the skin, as well as in patients receiving large doses of salicylates (for example, in rheumatoid arthritis), in patients with diabetes mellitus, glaucoma and cataracts.

Burning, itching, tingling and tingling sensations, paresthesia, folliculitis, acne-like eruptions, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, striae, prickly heat.

With local application of the drug Momat-S, the presence of very small, but measurable amounts of salicylates in the blood plasma was observed.

According to published data on the interaction of salicylates with other substances after ingestion or application to the skin, it is possible to change the action of the following medicinal compounds: tolbutamide (butamide), methotrexate, heparin, pyrazinamide, drugs that promote the excretion of uric acid, and drugs of indirect anticoagulants.

Other GCS and ammonium sulfate may affect salicylic acid content.

These interactions should be borne in mind when prescribing Momat-S together with these compounds.

Outwardly, apply a thin layer on the affected skin 2 times a day (morning and evening);

the maximum daily dose is 15 g.

Prolonged use of corticosteroids for topical application in excessive amounts can lead to suppression of the hypothalamic-pituitary-adrenal system and to secondary adrenal insufficiency.

If suppression of the hypothalamic-pituitary-adrenal system is observed, then the use of the ointment should be discontinued or the frequency of application should be reduced. 

In case of toxicity caused by salicylic acid, the use of Momat-S should be discontinued. Fluids should be administered to stimulate the excretion of salicylates in the urine.

Oral or intravenous administration of sodium bicarbonate and potassium salts can be prescribed as needed.

Appropriate precautions should be taken in the case of applying the ointment to large areas of the skin or intended long-term use (especially when used in pediatrics). Due to the fact that the ratio of skin surface and body weight in children is higher than in adults, children may be more sensitive to the action of GCS than adults, with the appearance of signs of suppression of the hypothalamic-pituitary-adrenal system and the manifestation of Cushing's syndrome. 

The ointment is not recommended for use with occlusive dressings, including diapers and diapers. The product is not intended for use on the face or in the groin and armpits. The ointment should not be used in ophthalmology. Children should receive the minimum amount of GCS required to achieve the effect. Long-term therapy with GCS can have an undesirable effect on the growth and development of children. 

In case of irritation, incl. excessive dryness of the skin and in case of allergic reactions, the use of Momat-S should be discontinued and appropriate treatment should be prescribed. If a concomitant skin infection develops, an appropriate antifungal or antibacterial agent should be used. 

If a positive response is not achieved quickly during treatment, the use of Momat-S should be discontinued until the infection is properly eliminated. It is necessary to assess the risk and expected effect of using Momat-S in the presence of the following diseases: diabetes mellitus, lesion or inflammation of peripheral vessels, irritation or infection of the skin.

GCS can cause a change in the appearance of the affected skin areas, which makes it difficult to make a correct diagnosis and leads to a slowdown in recovery.

Ointment for external use